Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Scambia

Showing results (401-410 of 551) with videos related to

Pageof 56
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinomaS Fiumicino, A Ercoli, G Ferrandina, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantationA Fattorossi, A Battaglia, L Pierelli, et al.
British Journal of Cancer|January 1, 1997
Prognostic significance of ras/p21 alterations in human ovarian cancerG Scambia, V Masciullo, P Benedetti Panici, et al.
Gynecologic Oncology|November 12, 2018
Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignanciesL Tortorella, J Casarin, K C Mara, et al.
Lupus|March 23, 2010
False-positive IgM for CMV in pregnant women with autoimmune disease: a novel prognostic factor for poor pregnancy outcomeS De Carolis, S Santucci, A Botta, et al.
Gynecologic Oncology|April 26, 2002
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancerG Ferrandina, F O Ranelletti, L Lauriola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patientsG Ferrandina, L Lauriola, G F Zannoni, et al.
British Journal of Cancer|November 26, 1999
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerG Ferrandina, A Fagotti, M G Salerno, et al.
European Journal of Clinical Investigation|December 21, 2000
Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight lossM Bossola, M Muscaritoli, R Bellantone, et al.
British Journal of Cancer|December 1, 1990
Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsG Scambia, F O Ranelletti, P B Panici, et al.
Pageof 56

Showing results (401-410 of 551) with videos related to

Sort By:
Pageof 56
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinomaS Fiumicino, A Ercoli, G Ferrandina, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2001
Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony-stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantationA Fattorossi, A Battaglia, L Pierelli, et al.
British Journal of Cancer|January 1, 1997
Prognostic significance of ras/p21 alterations in human ovarian cancerG Scambia, V Masciullo, P Benedetti Panici, et al.
Gynecologic Oncology|November 12, 2018
Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignanciesL Tortorella, J Casarin, K C Mara, et al.
Lupus|March 23, 2010
False-positive IgM for CMV in pregnant women with autoimmune disease: a novel prognostic factor for poor pregnancy outcomeS De Carolis, S Santucci, A Botta, et al.
Gynecologic Oncology|April 26, 2002
Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancerG Ferrandina, F O Ranelletti, L Lauriola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patientsG Ferrandina, L Lauriola, G F Zannoni, et al.
British Journal of Cancer|November 26, 1999
p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerG Ferrandina, A Fagotti, M G Salerno, et al.
European Journal of Clinical Investigation|December 21, 2000
Serum tumour necrosis factor-alpha levels in cancer patients are discontinuous and correlate with weight lossM Bossola, M Muscaritoli, R Bellantone, et al.
British Journal of Cancer|December 1, 1990
Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsG Scambia, F O Ranelletti, P B Panici, et al.
Pageof 56